𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

✍ Scribed by Daniel T. T. Chua; William I. Wei; Maria P. Wong; Jonathan S. T. Sham; John Nicholls; Gordon K. H. Au

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
103 KB
Volume
30
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

This single‐center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum‐based chemotherapy.

Methods

Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression.

Results

Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time‐to‐progression was 4 months, and median overall survival was 16 months.

Conclusion

Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. Β© 2008 Wiley Periodicals, Inc. Head Neck, 2008

πŸ“œ SIMILAR VOLUMES

Phase II study of oral S-1 for treatment
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma
✍ Kuniaki Shirao; Atsushi Ohtsu; Hideho Takada; Yasushi Mitachi; Kosei Hirakawa; N πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 98 KB

## Abstract ## BACKGROUND The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S‐1 (a combination of tegafur, 5‐chloro‐2,4‐dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorect

A phase II study of constant-infusion fl
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma
✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub

Phase II study of gemcitabine plus vinor
Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma
✍ Chuan-Cheng Wang; Jang-Yang Chang; Tsang-Wu Liu; Chin-Yu Lin; Yu-Chieh Yu; Ruey- πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 90 KB

Background. A phase II study was conducted to evaluate the safety and efficacy of a gemcitabine plus vinorelbine combination (GV) for patients with cisplatin-resistant nasopharyngeal carcinoma (NPC). Methods. Thirty-nine eligible patients received vinorelbine, 20 mg/m 2 , followed by gemcitabine, 1

Phase II trial of chemotherapy with 5-fl
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type
✍ Abdelkrim Taamma; Abdelrahim Fandi; Nacer Azli; Pierre Wibault; Nadia Chouaki; A πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 2 views

## BACKGROUND. The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT). The study included patients with metastatic or